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The immunological background of multiple sclerosis (MS) manifests as an altered reactivity against a diverse range of infections,
particularly with the Epstein-Barr virus. Although this could be only an epiphenomenon of a more generalised dysfunction of the
immunesystem inMS, it is alsopossible that a complex infectious background forms the basis of a speciﬁc immunedysregulation
ﬁnally causing the disease. It is thus suggested that the complex infectious background bears the key for an understanding
of the immune pathogenesis of the disease. It appears probable that improved standards of hygiene cause regulatory defects
in the immune system, allowing the abnormal expression of human endogenous retroviral (HERV) genes. On the basis of
epidemiological observations we describe how a failure of expansion or an eclipse of a subfraction of self-antigen-speciﬁc CD8+ T
cells mediating immune repair, and a deleterious mode of action of HERV gene products, could underlie the pathogenesis of MS.
1.Introduction
Studies on the viral aetiology of disease have traditionally
focused on exogenous viruses, but more recently attention
has turned to the role of human endogenous retroviruses
(HERVs) which comprise around 8% of the human genome
[1]. Although a number of diseases are associated with
abnormal formation of HERV-encoded gene products, it is
diﬃcult to establish whether such genetic expression is a
cause or an eﬀect of the disease process. Multiple sclerosis
(MS), the pathogenesis of which is poorly understood [2],
provides an ideal opportunity for the study of the way in
which HERVs may be involved in the various stages in the
evolution of a disease [3, 4].
Although it is widely accepted that there are strong
endogenous and exogenous components to the aetiology of
MS [5, 6], extensive studies failed to incriminate a single
endogenous or exogenous agent [7, 8]. Instead they point
to a complex infectious background to the pathogenesis of
the disease involving a multitude of exogenous infectious
agents and to a compromised immunological protective
background [9, 10]. The causal relationship of any given
agent to the aetiology of MS is diﬃcult to determine as most
or all the putative agents infect most human beings at some
stage of their lives. On the other hand, the HERVs coded for
by the human genome are part of the genetic background of
all humans [3, 4, 11]. Accordingly, any causative agent may
well be obscured.
2.Human EndogenousRetrovirusesinMS
Human endogenous retroviruses (HERVs) have entered the
human germ line successively over a period of millions of
years [3, 4, 11], and are present in the genome of all host
cells. Most HERVs are defective, having been inactivated
by negative selection and an accumulation of mutations
(deletions, termination codons, and frame shifts) and thus
most of their genetic loci are inactive [12, 13]. Some
reading frames have, however, maintained open and code
for a complete protein, such as the ERVWE1 locus on
chromosome 7q21 which codes for syncytin-1, and one
member of the HERV-W family, the multiple sclerosis-
related virus (MSRV), can form complete virions under cer-
tain circumstances [14]. Moreover, it is well established that2 Autoimmune Diseases
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well as endogenous retroviruses in other species, such as
rodents, ovines, and birds, can be cause of neurological and
malignant diseases [15].
In this respect it is of interest that the presence of HERV
sequences, and in particular those of the γ-retroviruses
HERV-W/MSRV and of HERV-H/F, have been found in
association with MS [12, 16, 17], that the expression of
ERVWE1/MSRV in brain tissue from MS patients has been
reported [18, 19], and that the presence of such sequences
in the CSF has been claimed to be higher in MS than in
controls [14, 20, 21]. Another group claimed that it is only
syncytin that is expressed at higher levels in brains of MS
patients[22], although the techniques used to show this have
been criticised [23]. In addition, increased levelsofantibody
reactivity tospeciﬁc γ-retroviral HERVGagandEnvepitopes
have been found in serum and CSF from MS patients [12],
and these antibody levels are related with the activity of the
disease [4]. The HERV-W encodedEnv (ERVWE1, syncytin)
is upregulated in glial cells in active MS lesions and, when
expressed as a construct in astrocytes, has been shown to
induce oligodendrocyte cell death via redox-reactants [24],
as well as inducing an autoimmune cascade [3].
Despite of 20 years of research, the role of HERVs as
pathogens is still controversial but, nevertheless, they are the
leading candidates for a link between genetic predisposition
and environmental factors in a disease such as MS.
3.Are ExogenousViruses andChlamydia
Involved inthe PathogenesisofMS?
Besides the HERVs as described above, there are at least
three groups of exogenous infectious agents that can be
grouped according to the nature of the observations that
putatively link them to MS. The ﬁrst group is exempliﬁed
by measles, varicella, and herpes simplex viruses, but it
may contain many more potential members. The second
group comprises the human herpes virus 6 (HHV-6) and
Chlamydia pneumonia and the third group is represented
only by the Epstein-Barr virus (EBV) which has emerged as
the leading candidate among the putative pathogens.
In the premeasles vaccination era it was observed that,
in the history of MS patients, there were more clinically
manifest cases of measles that were experienced only later
in life, as compared with controls [7, 8]. Moreover, the
concentrationofmeasles-speciﬁc antibodieswasshowntobe
consistently higher in MS patients [7, 8]. The introduction
of measles vaccination in early childhood, however, had no
striking impact on the epidemiology of MS [8, 25]. A similar
situationisobservedwithinfectionbyvaricellaas,incontrast
to previous studieson mostly adult patients, observations on
a cohort of children showed that a history of chickenpoxwas
associated with a reduced risk of MS (Odds ratio 0.58) [26].
Since the diﬀerences between prevalence of infectious
disease or of a speciﬁc antibody between the patient and
control groups are small, large groups must be studied to
reveal signiﬁcant diﬀerences. On this basis, at least 12 can-
didate infections, including measles and varicella, could have
an association with MS [7–9, 27]. Problems of interpretation
of such ﬁndings are illustrated by herpes simplex. Although
MS patients have a higher prevalence of antiherpes simplex
type 2 (HSV-2) antibody as compared with controls, this
does not reﬂect a higher prevalence of HSV-2 infections
in the patients; the reason being an elevated concentration
of speciﬁc antibodies generated by infection with herpes
simplex virus 1 (HSV-1) that cross-react more strongly in
MS patients than in controls with the diagnostic HSV-2
antigen [9]. Moreover, a recent study on patients with MS
commencing in childhood permitted a check in parallel for
an association of speciﬁc infections to MS by means of
elevated speciﬁc antibody. This identiﬁed measles, varicella,
and herpes simplex viruses (P<. 0001) as the leading
candidates, whereas an MS association for others including
inﬂuenza, parainﬂuenza and rubella viruses (P = .035,
.029 and .054, resp.), was less clear, questionable, or not
conﬁrmed [9].Althoughthere areinterpretational problems,
these observations ﬁnd a parallel in studies on the synthesis
of speciﬁc antibodies in the brain against the same range
of pathogens, namely measles, varicella, herpes simplex, and
rubella [28–30].
Association of infections with human herpes virus 6
(HHV-6) and Chlamydia pneumoniae (Cpn) to MS are
weaker but serological parameters diﬀer qualitatively from
controls and it is possible that active, possibly chronically
active, infections with these pathogens synergize with EBV
to produce a dysregulated immune response. These two
infections are signiﬁcantly associated with MS.Thus elevated
IgM antibody levels against Cpn in paediatric MS patients
are indicative of current or recent active infection at the time
of onset of MS [9]. A meta-analysis of 26 studies showed
that, despite interstudy variability, patients with MS were
signiﬁcantly more likely than healthy controls or those with
other neurological diseases to have detectable levels of Cpn
DNA in their CSF, although the authors concluded that this
ﬁnding did not establish an aetiological relationship [31].
In the case of HHV-6, repeated phases of coinciding virus
activity with EBV in patients with MS have been described
[32]. Moreover, there is an interesting series of systematic
studies on targets of speciﬁc B and T cells that are detected
more frequently in MS as compared with controls [33,
34]. These studies were originally intended to identify the
potentialtarget(s)ofautoimmuneprocesses. Itwas,however,
not possible to conﬁrm the higher frequency of such B and T
cells speciﬁcities insubsequentstudies, butotherspeciﬁcities
became apparent and another aspect emerged. All the MS-
associated epitopes had sequences homologous to those in
proteins of EBV, HHV-6 as well as of Cpn, indicative ofsome
interrelationship between the immune responses against the
three diﬀerent pathogens [10].
4.ObservationsonEBVInfection
In recent years interest has focused on the role of infection
withEBVintheaetiologyofMS[35–38].Ameta-analysis has
establishedthat>95%ofallpatientswithMShaveserological
evidenceofpriorEBVinfection, compared to87% in control
subjects [39]. There is, however, no serological evidence ofAutoimmune Diseases 3
reactivation or active EBV infection in the patients at the
time of onset of MS [9, 37, 40], and claimed extensive
EBV infection of lymph follicles in the brain of MS patients
[41] was not conﬁrmed in subsequent studies [42–44]a n d
remains an open question [45]. Furthermore, there is a lag
phase of several years or a decade or more between EBV
infection in the patients and the clinical manifestation of
MS [46]. During this rather long time period, EBV-speciﬁc
antibody may well have dropped below detectable levels in
some persons. Also, taking into account the distribution of
speciﬁc antibody concentrationsin the study groups, itis not
only possible butindeed likelythat in the patient group there
are virtually no EBV-na¨ ıve persons and, accordingly, past
EBV infection has been postulated as a necessary condition
for development of MS [9, 10, 37]. Accordingly, primary
EBV infection appears to be extremely rare in those with
established MS[46],and in a longitudinalfollowup ofalarge
cohort of EBV-negative young adults, MS was observed to
occur only subsequent to EBV infection [47].
In addition some qualitative diﬀerences were apparent in
the antibody response to EBV in the patients with MS and
the controls; in particular, the former had notably elevated
antibody levels against the EBNA-1 protein of EBV [30, 37,
40, 48, 49]. The local synthesis of anti-EBNA1 antibody in
CSF has been described in several studies [30, 49–53]. It was
also demonstrated that the risk of developing MS increases
withthe levelofantibodyto thisvirus [48]. The link between
EBV infection and the risk of MS is, however, unclear and
is not easily determined in an adult population since the
great majority of controls are, from the third decade of life,
likewise infected by this virus.
Notwithstanding, there are a number of hypothetical
mechanisms by which EBV might induce MS [36, 54–
56], though none of those suggested convincingly explain
the pathogenesis of the disease, and it appears more likely
that other infections synergize with EBV to produce a
dysregulated immune response years or a decade before
the clinical onset of MS. Moreover, the pathology of MS,
characterised by widespread blood-brain barrier defects and
a multifocal involvement of grey and white matter, argues
against a conventional role for a presumed viral aetiology
[57].
5.DarwinianMedicine
Attention has recently focused on environmental factors
associated with theincrease in the incidenceof severalclasses
ofdisease in the industrially developednations. The concept,
forming the basis of the emerging discipline of “Darwinian
medicine” [58], is that hygiene-related factors isolate the
human population from micro-organisms, both pathogens
and, probably more importantly, commensals, that are
crucial to the establishment of beneﬁcial immunoregula-
tory networks. Thus, in principle, an “interkingdom cross-
talk” between microbes and the human host can establish
patterns of immune reactivity that prevent various allergic,
autoimmune, and inﬂammatory diseases while a failure of
such cross-talk can facilitate them [59]. One consequence
of improved hygiene is that certain infections that were
previously regularly encountered in infancy now occur at a
much later time in life and after other infections may have
altered the patterns of immune responsiveness. Infection
by EBV is a good example, and it has been postulated
that various other infections acquired before EBV may
aﬀect immunoregulatory networks, thereby leading to an
attrition or eclipse of those regulatory T cells (Tregs) that
would otherwise protect against MS [10]. In this context,
Tregs, though essential to immune function, may in some
circumstances induce harmful eﬀects and have therefore
been termed a “dangerous necessity” [60].
Accordingly, a critical determinant of MS risk could be
a compromised number or activity of protective Tregs[ 61,
62]. During an active and speciﬁc T cell-mediated immune
response there could well be a competition with other kinds
of T cells, most likely T-helper-cells, recognising the same
epitope as the Tregs or epitopes closely spatially situated
on the relevant antigen(s). As a consequence certain T-
helper cell populations, that induce production of speciﬁc
antibody, could become expanded and, thus, account for
the diverse rise in antibody levels as epiphenomena with
little or no pathologic importance. Notwithstanding, the
local production of measles, varicella, or rubella-speciﬁc
antibodies in the central nervous system can be useful
for diagnosis [28–30], and the production of anti-HERV
antibodies may become of use as prognostic factor for MS
disease [4, 63].
6.TargetEpitopesandHLA-Polymorphism
On the supposition that the diverse MS-associated infectious
agents express epitopes that generate regulatory and eﬀector
T cells involved in the prevention of, or an enhancement of
risk of, MS, the challenge was to identify the relevant epitope
or epitopes.
The EBV EBNA-1 protein is the most likely candidate
to express an epitope that could aﬀect Tregs, since the
concentration of speciﬁc antibody against this protein is,
as mentioned above, particularly and signiﬁcantly elevated
in MS, in both children and adults [9, 64]. Moreover, the
E B N A - 1p r o t e i ni se x p r e s s e di nl a t e n tE B Vi n f e c t i o n ,a n dT
cells recognising EBNA-1, play a key role in immune control
of EBV in healthy persons [64]. Under these circumstances
the number of epitopes of T-helper cells recognised on
EBNA-1 is very limited but in MS many more epitopes
across the entire C-terminal domain of the protein are
recognised [65]. This “epitope spreading” could well be
induced by prior and/or simultaneous infections by the
candidate pathogens mentioned above, notably HHV-6 and
Chlamydia pneumoniae, as these bear many homologies
to the additional epitopes on the EBNA-1 protein [10].
This altered epitope recognition could divert the immune
response away from the single putatively protective Treg
epitope (which is likely to be harboured within the sequence
FENIAEGLRALLARSHVER) and to the generation of an
alternative range of competing T-helper cells.
The further challenge is to determine the host target for
protective and altered, nonprotective, patterns of immune4 Autoimmune Diseases
reactivity, and a likely candidate would be an epitope
of a HERV-W peptide since, beside the few functional
HERV-W proteins mentioned above, there are some open
reading frames that code for hypothetical HERV peptides
[10]. A candidate HERV epitope with the amino acid
sequence MPVPSAPST was identiﬁed on a hypothetical
HERV peptide and shown to have homologies in all the
pathogens to which elevated antibody concentrations are
foundinMSpatients,includingEBV,measles,varicella, HSV,
Chlamydia, HHV-6, inﬂuenza, parainﬂuenza, rubella, and
others [10]. It was postulated that the eﬀector T cell speciﬁc
for this candidate epitope would most readily cooperate
with the above-mentioned Tregs to support a supposed
MS-protective immune response when the homologies of
the respective speciﬁc target sequences are present on the
same viral protein. This situation is realized with three
pathogens: measles, varicella/zoster, and herpes simplex
virus (type 1 and 2) [10]. Interestingly, on the basis of ele-
vated antibody concentration, measles, varicella/zoster, and
herpes simplex virus 2 have a very clear association with MS
in children (P<. 0001, with Bonferroni-Holm correction
for multiple testing), whereas the MS association of the
other pathogens is dubious or unconﬁrmed [9]. It must
be stressed that gene transcripts of 21 of 25 open-reading
frames with an initiating start codon for the hypothetical
HERV peptide have been found in association with MS
[10]. This gene transcript is coded on the complementary
strand of the HERV-W Env gene region. To our knowledge
this would be the ﬁrst example of genetic information on
the noncoding DNA strand of the human genome being
implicated in immune processes relevant to health and
disease!
It istherefore possible in principle touse epidemiological
data and genetic databases to identify candidate targets
of the relevant immune cells, and veriﬁcation may come
from future studies on HLA polymorphism. The relevance
of the HLA polymorphism, for example, in MS has been
demonstrated very clearly [66, 67], but though over 99% of
individuals appear to be genetically incapable of developing
MS, no speciﬁc gene making a major contribution to
susceptibility to MS has yet been identiﬁed. In the light of
the framework presented here, there is a need to investigate
whether the critical determining factor in such susceptibility
is a genetically determined absence of, or defect in, HLA
molecules able to present the relevant peptides for supposed
MS-protective Tregs[ 61, 62]a n dT - e ﬀector cells and the
presence of HLA molecules presenting homologous peptides




The suggested mechanism of pathogenesis of MS presented
here, based on the infectious background of the patient, is a
novel one, but it may have a precedent in the pathogenesis
of what, at ﬁrst view, appears a completely unrelated disease,
namely, melanoma [68–70]. There are parallels between the
two diseases as in both it has been postulated that a HERV
associated pathology, based on expression of HERV-encoded
genes and the presentation of HERV-encoded peptides by
HLA molecules, may be of critical relevance to pathogenesis
[68, 69]. As proposed for MS, there is evidence that immune
recognition of, and response to, such peptides contribute
to the immune surveillance of the initiating events of the
pathogenesis of melanoma years or decades before the onset
of clinical disease. On the other hand, there are major
diﬀerences between the two diseases, with MS being more
complex. In the case of melanoma, the available evidence
indicates that a major component of immune-mediated
protection results from the induction, by a range of natural
infections and vaccinations, of populations of eﬀectorT cells
that cross-react with a HERV-encoded epitope, HERV-K-
MEL, on a peptide coded for by an open reading frame of
a HERV-K, and expressed on the surfaces of malignantly
transformed melanocytes [69–71]. Indeed, vaccination with
BCG or vaccinia early in life, or with yellow fever vaccine
in adults, confers around 50% protection against melanoma
later in life [68, 72, 73]. There is, however, no evidence
that the mechanism for eclipse of protective regulatory cells
as postulated for MS plays a role in the pathogenesis of
melanoma.
It must be emphasised that HERV-encoded peptides
are self-antigens and thus, in principle, able to be rec-
ognized by self-speciﬁc CD8+ T cells, the developmental
biology and function of which has attracted considerable
interest in recent years [74–76]. These cells belong to a
distinct genetic lineage and have diﬀerent developmental
requirements than those of conventional CD8+ T cells. They
undergo clonal proliferation when activated by infectious
agents or vaccines bearing homologous epitopes [77], and
may persist as self-speciﬁc memory cells for long periods of
tim e.I tis ,ho w ev er ,im portantt onot ethats elf -s peciﬁ cCD8 +
T cells do not necessarily result in autoimmune reactions
deleterious for the host but can instead result in immune
repair.
In this context, while much attention has been paid to
cell-mediated immune reactions resulting in cytotoxicity,
much less interest has been shown towards mechanisms of
cell repair, particularly in circumstances where conservation
of cells, such as in the central nervous system, is of great
importance. One such repair mechanism that has been
studied involves gangliosides of the neolacto series, espe-
cially LM1, which are transferred from leucocytes to target
cells by direct cell-to-cell contact [78–81]. In this context,
gangliosides may be involved in the process of methylation
of DNA which is the most important means by which a
somatic cell can repress or silence the genetic expression
of HERV-encoded genes [82, 83]. Thus, diﬀerential display
analysis of gene expression established that LM1 mediates
suppression of retroviral RNA [68, 79]. A mechanism for
this is suggested by the ﬁnding that LMI induces S-adenosyl-
homocysteine-hydrolase, an enzyme essentially involved in
the generation of active methyl groups required for the
process of methylation, as well as inducing a kelch-1-
like protein, one of a family of proteins that mediate
transcriptional repression [84].Autoimmune Diseases 5
8.OverexpressionofHERVEnv Proteins
The observations summarised above raise the question of
how abnormal HERV expression can induce pathological
changes at the cellular level and how these changes can
be prevented [3, 70, 84]. One aspect that is dealt with
in the various papers in this special issue of the journal
is the diversity of mechanisms that induce autoimmune
phenomenainMS,anaspectthathasbeencriticallyreviewed
elsewhere [85]. Another aspect is disturbed redox processes
[24, 86, 87], as oxidative stress is certainly implicated in
demyelinating disorders [88].
Retroviral Env proteins are glycoproteins that are able
to cause neuroinﬂammation, neurodegeneration, and endo-
plasmic reticulum stress [86]. In MS the ERVWE1 Env,
syncytin-1, is particularly overexpressed in glia where it
inducesendoplasmatic reticulum stress leading to the induc-
tion of free radicals that damage nearby cells [24, 86, 87].
The involvement of diﬀerent cell components has been
demonstrated, notably ASCT1, a receptor for syncytin-1,
and a neutral amino acid transporter which were selectively
suppressed in astrocytes. Syncytin-1 induces the expression
of the endoplasmatic reticulum stress sensor (OASIS) and
overexpresion of this sensor in astrocytes increases levels of
inducible NO synthase with ensuing oligodendrocyte injury.
Studies on transgenic mice gave insights into the role and
mechanisms of HERV Env proteins in causing neuroinﬂam-
mation and autoimmune processes, and conﬁrmed human
observations [86].
In melanoma, epidemiological observations led to the
suggestion that HERV-K Env induced biosynthesis of
“melanoma-melanin” via reduced levels of glutathione-
peroxidase [68, 88, 89]. This modiﬁcation of melanin is able
to incorporate more heavy metal ions as compared with
physiological eumelanins, in particular mercury, and tends
to become oxidatively charged. Melanoma-melanin, respon-
sible for the black colouration of melanomas, is detectable
in dysplastic and congenital naevi cells, the presumed
precursors of melanoma, but not in normal melanocytes.
Melanin pigments have a very long life span and oxidatively
charged melanoma melanin can thus catalyse the formation
of harmful long-living reactive oxygen species and radicals
over long periods of time, whereas normal melanin destroys
them. Aﬀected cells are therefore very vulnerable to any kind
of oxidative stress, paving the way to cell degeneration and
to malignant transformation through chromosome damage
[90].
Moreover, in melanoma, interest has focussed on a
distortion of the immune response caused by expression
of HERV-encoded proteins leading to tumour escape and
autoimmuneprocesses [69],althoughquestionsof causeand
eﬀect remain.
These considerations on melanoma raise the question of
whether similar mechanisms involving HERV-encoded pro-
teins and melanin pigments could operate in MS. Although
there is no direct evidence, there are some suggestive factors.
Among the several environmental risk factors for MS [6],
a leading one is a low level of bioactive vitamin D3,
but it is still controversial whether any and, if so, which
of the many actions of this vitamin is critical for MS
[91]. It has been suggested that low levels of this vitamin
cause, via γ-glutamyl-transpeptidase, a reduction in the
intracellular levels of glutathione, as has been demonstrated
in rat astrocytes [92]. The risk-enhancing eﬀect of low
vitamin D3 levels appears to commence during early in
utero development as persons born in November/December
have the least MS risk while those born in May/June have
the highest risk. This diﬀerence is statistically signiﬁcant
[93]. The long-lasting impact of this eﬀect may result from
favouring the peroxide driven biosynthesis of melanoma-
like melanin and by the long-living nature of the polymeric
melanin redox pigments including pro-oxidative variants.
Cigarette smoking, particularly when started early in life, is
ar i s kf a c t o rf o rM S[ 94, 95], and for an early conversion to
clinically deﬁnite multiple sclerosis [96]. The mechanism of
this risk could be the generation of reactive oxygen species.
9.Conclusions
In view of the possible mechanistic link between the
pathogenesis of melanoma and MS, further studies on the
role ofHERVsin MS, and their comparison with HERV-Kin
melanoma are indicated.
Although the two diseases under consideration, MS and
melanoma, are quitediﬀerent,there are parallels in that both
conditions develop in tissues originating from the neural
crest and that both can be explained in terms of “Darwinian
medicine” [58, 69]. A complex pattern of exogenous infec-
tionsand activation ofendogenousretroviruses isapparently
underlying the aetiology of both conditions.
Combining the analysis of epidemiological data with
genetic data bank entries of infectious pathogens and of
humans, it is possible to identify deﬁcits within the regula-
tory networks of the immune system. We are convinced that
on this basis it will become possible in the future to establish
rational preventive and therapeutic measures for MS.
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